Saturday, November 22, 2014 12:17:31 PM
Is this agreement in play? The below chart shows the numbers that would have to be met to retain the exclusive rights to the products. What time zone are you in?
SCHEDULE – D
Mutually accepted Sales Target
Mobile Clinics
Year
Estimated Value
Remarks
2
Q4
2011
$14.575 Million
To retain Exclusivity for Nigeria
3
Q1 - Q2
2012
$21.863 Million
To retain Exclusivity for Nigeria
2
Q3 – Q4
2012
$14.575 Million
To retain Exclusivity for Nigeria
3
Q1 - Q2
2013
$21.863 Million
To retain Exclusivity for Nigeria
2
Q3 – Q4
2013
$14.575 Million
To retain Exclusivity for Nigeria
3
Q1 - Q2
2014
$21.863 Million
To retain Exclusivity for Nigeria
2
Q3 – Q4
2014
$14.575 Million
To retain Exclusivity for Nigeria
3
Q1 - Q2
2015
$21.863 Million
To retain Exclusivity for Nigeria
2
Q3 – Q4
2015
$14.575 Million
To retain Exclusivity for Nigeria
3
Q1 - Q2
2016
$21.863 Million
To retain Exclusivity for Nigeria
2
Q3 – Q4
2016
$14.575 Million
To retain Exclusivity for Nigeria
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM